In addition, CD8/CD3 ratio was higher in RBM10 mutant group (P=0.019, Figure 5E), and CD4/CD3 ratio was lower (P=0.001, Figure 5F), which further proved that the fraction of anti-tumor T cells are higher in patients with RBM10 mutations. Here, CD4 is linked to neoplasm.